Particulars		100	As at	Rs in Lakh
ASSETS		Notes	March 31, 2025	As at
CONSTRUCTION OF THE STATE OF TH			27 2025	March 31, 2024
I. Non-current assets				
(a) Property, plant and equipment(b) Right of use assets		5	1,359.04	1 120 10
(c) Financial assets		31	67.63	1,426.12
(i) Investments			07.05	81.72
(ii) Other financial assets		6 (a)	485.71	365.69
	tal	6 (f)	23.89	22.89
10	otal non-current assets		1,936.27	1,896.42
II.Current assets				
(a) Inventories		8	depended area	
(b) Financial assets		0	355.66	215.11
(i) Trade receivables		6 (b)		
(ii) Cash and cash equivalents		6 (d)	369.36	574.89
(iii) Bank balances other than (ii) a		6 (e)	73.62	4.88
(IV) Loans		6 (c)	101.00	307.29
(v) Others financial assets		6 (f)	0.23	245.27
(c) Current tax assets (net)		9	3.55	38.28
(d) Other current assets		7	FF1 10	9.00
	Total current assets		551.18 1,454.60	375.04
	All man a residence in account a foreign of the second of	10	1,434.60	1,769.76
	_	-		
	Total Assets	S = 5	3,390.87	3,666.18
QUITY AND LIABILITIES				
•				
quity				
(a) Equity share capital		10	889.46	namena mon
(b) Other equity		11	1,297.77	889.46
	Total equity	-	2,187.23	1,699.85
IABILITIES	1. To A. Decreto (1. 17 To A. 1844 T .)		2/10/123	2,589.31
Non-current liabilities				
(a) Financial liabilities				
(i) Borrowings	12	2 (a)	138.68	205.07
(ii) Lease Liabilities		31	60.62	205.97
(b) Long-term provisions		13	27.17	52.51
(c) Deferred tax Liability		23		28.02
Total n	on-current liabilities		152.04 378.51	120.49
		7	3/8.51	406.99
Current liabilities (a) Financial liabilities				
(i) Borrowings				
(ii) Lease Liabilities	12	(a)	463.26	402.11
(iii) Trade payables	3	31	19.11	403.11 33.54
	12	(b)		33.54
 Total outstanding dues of micro 	enterprises and		120 = 1	
small enterprises			48.36	24.57
 Total outstanding dues of creditors of creditors 	other than micro			
enterprises and small enterprises			75.27	67.06
(iv) Other financial liabilities	4.5			07.00
(b) Other current liabilities	12		138.52	38.38
(c) Short-term provisions	1		52.37	79.57
(d) Current tax Liability (net)	1		17.22	23.65
	al current liabilities	HA	11.02	-
			825.13	669.88
Total E	quity and Liabilities		2 200 00	
		-	3,390.87	3,666.18
accompanying summary of material account	ing policies 3		2	_
				₹.

The accompanying notes are an integral part of these Financial Statements.

As per our report of even date For Sorab S. Engineer & Co. Chartered Accountants

Firm Registration No.110417W

CA. Chokshi Shreyas B.

Partner Membership No. 100892

Ahmedabad Date: May 17, 2025 For and on behalf of Board of Directors of

Synbiotics Limited

Mohal K Sarabhai Managing Director DIN: 00334441

Salt Lake City, USA Date : May 17, 2025

Anurag Mehta Director DIN: 09756365

Vadodara Date : May 17, 2025

CÍN: U24232GJ1960PLC000992

Statement of Profit and Loss for the year ended March 31, 2025

			Rs in Lakhs
Particulars	Notes	Year ended March 31, 2025	Year ended March 31, 2024
I. Income		7.10.101.027.2025	March 31, 2024
Revenue from operations			
Sale of Products	15	1,491.96	1 420 42
Revenue from operations		1,491.96	1,420.42 1,420.42
Other income	16	312.10	
Total income (I)		1,804.06	318.97 1,739.39
II. Expenses		1,004.00	1,739.39
Cost of material consumed	17	208 62	
Changes in inventories of Finished goods and Work-in-progress	18	298.62	146.40
Employee benefits expense	19	(35.65)	108.35
Finance costs	20	384.38	363.87
Depreciation and amortisation expense	21	69.23	64.10
Other expenses	22	125.93	117.95
Total expenses (II)	22	1,082.75	997.52
		1,925.26	1,798.19
III. Profit/(Loss) for the year before tax (I-II)			
IV. Exceptional items	22	(121.20)	(58.80)
V. Profit before tax = (III-IV)	23	240.00	
(111 14)		(361.20)	(58.80)
VI. Tax expense	24		
Current tax	24		
Short/(Excess)provision related to earlier years		_	-
Deferred Tax charge / (credit)		9.95	
Total tax expense		31.39	(21.53)
		41.34	(21.53)
VII. Profit/(Loss) for the year (III-IV)		(402.54)	
VIII. Other Comprehensive Income		(402.54)	(37.27)
Items that will not be reclassified to profit or loss:			
Re-measurement gains / (losses) on defined benefit plans	1/2/50		
Income tax effect on above	28	0.62	(6.43)
Net Other Comprehensive Income/(Loss) not to be	24	(0.16)	1.62
reclassified to profit or loss in subsequent periods			
reduces the profit of loss in subsequent periods		0.46	(4.81)
Total Other Comprehensive Income/(Loss) for the year (net			
of tax)		0.46	(4.54)
n tax)		0.46	(4.81)
IX. Total Comprehensive Income/(Loss) for the year, net of tax	((V-VT)	(402.08)	(42.00)
	. (• • • • • • • • • • • • • • • • • •	(402.08)	(42.08)
C. Earnings per equity share			
Nominal value per share - Rs. 10 (Previous year - Rs. 10)			
Basic and Diluted - Rs.	30	(452.57)	(41.90)
Coo accompanying automatical in the control of the	5000	(.52.57)	(41.50)
See accompanying summary of material accounting policies	3		

The accompanying notes are an integral part of these Financial Statements.

As per our report of even date For **Sorab S. Engineer & Co.** Chartered Accountants

Firm Registration No.110417W

CA. Chokshi Shreyas B.

Partner

Membership No. 100892

Ahmedabad

Date: May 17, 2025

For and on behalf of Board of Directors of

Synbiotics Limited

Mohal K Sarabhai

Managing Director DIN: 00334441

Salt Lake City, USA Date: May 17, 2025 Anurag Mehta

Director DIN: 09756365

Vadodara 2025 Statement of Cash Flows for the year ended March 31, 2025

Particulars	Year end		Year ende	Rs in Lakh
A Operating activities	March 31, 2	025	March 31, 2	
Profit/(Loss) Before taxation Adjustments to reconcile profit before tax to net cash flows: Depreciation /Amortization Interest Income Dividend Income Finance Costs Excess provision written back (Profit)/Loss on sale of Property. Plant & Equipment Loss on remeasurement of Lease Liability Guarantee commission	125.93 (28.53) (0.98) 69.23	(361.20)	117.95 (47.86) (0.98) 64.10 (5.24)	(58.80
Sundry debits/credit written off (Net)	0.11		(4.54)	
Operating Profit before Working Capital Changes Working Capital Changes: (Increase) / Decrease in Inventories		171.04 (190.16)	(14.71)	108.72 49.92
(Increase) / Decrease in Inventories (Increase) / Decrease in trade receivables (Increase) / Decrease in other assets (Increase) / Decrease in other financial assets (Increase) / Decrease in Other Bank Balances Increase / (Decrease) in Other Bank Balances Increase / (Decrease) in other liabilities Increase / (Decrease) in other financial liabilities Increase / (Decrease) in provisions Net Changes in Working Capital	(140.55) 205.42 (176.14) - 206.29 32.00 (27.20) 100.14 (6.66)		119.26 (124.77) (177.64) - - 49.72 28.51 18.90 5.65	
Cash Generated from Operations		193.30	13.65	(66.72)
Direct Taxes paid (Net of Income Tax refund)		3.14		(16.80)
Net Cash flow received / (used in) Operating Activities		10.07		(3.45)
Cash Flow from Investing Activities Purchase of Property, Plant & Equipment Proceeds from disposal of Property, Plant & Equipment Changes in Loans and advances Investment in Joint Venture Dividend Income Interest received Changes in other non-current financial assets Net Cash flow received / (used in) Investing Activities	(28.11) - 245.04 (120.02) 0.98 63.26 (1.00)	13.21	(71.49) 13.87 0.03 - 0.98 22.78	(20.25)
Cash Flow from Financing Activities		100.15		(33.83)
Changes in capital advances Repayment of long term borrowings Changes in short term borrowings Repayment of Lease Liabilities Financial Guarantee commission Finance Costs Net Cash flow received / (used in) Financing Activities	(67.29) 60.15 (36.89) (60.59)		27.97 79.37 (33.55) 4.54 (56.84)	
		(104.62)		21.49
Net Increase/(Decrease) in cash & cash equivalents Cash & Cash equivalent at the beginning of the year Cash & Cash equivalent at the end of the year Figures in brackets indicate outflows.		68.74 4.88 73.62		(32.59) 37.47 4.88

Particulars Cash and cash equivalents comprise of: (Note No. 6(d))	Year ended March 31, 2025	Year ended March 31, 2024
Cash on Hand		
Balances with Banks	1.24	0.79
Cheque on Hand	72.38	4.09
Cash and cash equivalents	0.00	0.00
The accompanying notes are an integral part of these Financial Statements.	73.62	4.88

Disclosure under Para 44A as set out in Ind AS 7 on cash flow statements under Companies (Indian Accounting Standards) Rules, 2015 (as amended)

articulars of liabilities				Non Cash Ch	anges	May Sort State of the Control of the
rising from financing activity Borrowings:	Note No.	As at April 1, 2024	Net Cashflow	Impact Due to Ind AS 116	Other Changes*	As at March 31, 2025
Long term borrowings Short term borrowings Lease Liabilities	12(a) 12(a)	205.97 403.11	(67.29) 60.15	-	•	138.68
Total	31	86.05 609.08	(36.89)	30.57 30.57		463.2 79.7 601.9

articulars of liabilities				Non Cash Ch	anges	
rising from financing activity Borrowings:	Note No.	As at April 1, 2023	Net Cashflow	Impact Due to Ind AS 116	Other Changes*	As at March 31, 2024
Long term borrowings Short term borrowings Lease Liabilities	12(a) 12(a)	178.00 323.74	27.97 79.37	-	-	205.97
Total	31	27.70 501.74	(33.55) 107.34	91.90 91.90		403.1 86.0

^{*} The same relates to amount charged in statement of profit and loss accounts.

Note:

1) The cash flow statement has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) "Statement of Cash Flows"

As per our report of even date For Sorab S. Engineer & Co. Chartered Accountants Firm Registration Ng 110417W

CA. Chokshi Shreyas B. Partner Membership No. 100892

Ahmedabad Date : May 17, 2025

For and on behalf of Board of Directors of

Mohal K Sarabhai Managing Director DIN: 00334441

Salt Lake City, USA Date: May 17, 2025

Anurag Mehta Director DIN: 09756365

Vadodara Date: May 17, 2025

Synbiotics Limited
CIN: U24232GJ1960PLC000992
Statement of Changes in Equity for the year ended March 31, 2025
Rs in Lakhs

A. Equity share capital	Note 10		
Ac at March 24 2024			
Add : Issue of Equity Share special	889.46		
As the same of Equity Share capital			
AS at March 31, 2025	889.46		
R Othor canit			
b. Other equity	Attributable to	Attributable to the equity holders	Rs in Lakhs
	Reserves	Reserves and Surplus	
Darticulare			
	Securities premium	Retained Earnings	Total Other Equity
	Note 11	Note 11	
Balance as at April 1, 2023 (Loss) for the year	869.50	872.43	
Other comprehensive income / (loss) for the year	r	(37.27)	(37.27)
Total Comprehensive income / (loss) for the year	1	(4.81)	
Balance as at March 31, 2024	0000	(42.08)	
Balance as at April 1, 2024	809.50	830.35	
(Loss) for the year	869.50	830.35	
Other comprehensive income / (loss) for the year	7.1	(402.54)	
Total Comprehensive income / (loss) for the year	1	0.46	
Balance as at March 31, 2025	0	(402.08)	
	06.600	428.27	

(4.81) (42.08) 1,699.85 1,699.85 (402.54) 0.46 (402.08) 1,297.77

The accompanying notes are an integral part of these Financial Statements.

As per our report of even date For Sorab S. Engineer & Co. Chartered Accountants Firm Registration No. 110417W

CA. Chokshi Shreyas B. Partner

Membership No. 100892

Date: May 17, 2025 Ahmedabad

For and on behalf of Board of Directors of Synbiotics Limited

Managing Director DIN: 00334441

Salt Lake City, USA Date : May 17, 2025

Mohal K Sarabhai Anurag Mehta

Vadodara Director DIN: 09756365

Date: May 17, 2025

Notes to the Financial Statements CIN: U24232GJ1960PLC000992 **Synbiotics Limited**

Note 5: Property, plant and equipment

50.00 764.12
50.00 764.12
ì
50.00 764.12
- 200.04
- 28.21
228.
- 256.41
50.00 507.71
50.00 535.87

For properties pledged as security, refer Note 12 (a) 333

Refer Note 26 for disclosure of contractual commitments for the acquisition of property, plant and equipment. In accordance with the Ind AS 36, 'Impairment of Assets', the Company has reassessed its Property, plant and equipment and is of the

view that no impairment is considered to be necessary in view of its expected realisable value. Title deeds of immovables properties are held in the name of the company. 4

Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 6 : Financial assets

6 (a) Investments

Particulars	Face Value		Rs in Lakh
Non-current investment	per share in	As at March 31, 2025	As at March 31, 2024
(a)Investment in Equity Shares of Joint Ventures (Measured at Cost) - Unquoted			
47,92,103 shares of COSARA Diagnostics Pvt. Ltd. (Previous vear 35,91,863 shares)	10	479.21	359.19
(b)Investment in Equity Shares of Others (Measured at FVOCI) - Unquoted*			339.19
26,000 shares of Kalupur Commercial Bank Previous year 26,000 shares) Total Investments	25	6.50	6.50
aggregate amount of quoted investments		405.74	22/32/5
aggregate amount of unquoted investments		485.71	365.69
aggregate impairment in value of investment The management has assessed that the carrying value of the		485.71	365.69

6 (b) Trade receivables - Current

Particulars	As at	Rs in Lakhs As at
Unsecured Considered good	March 31, 2025	March 31, 2024
Total	369.36	574.89
Votace	369.36	574.89

- Notes:

 1) No trade receivables are due from directors or other officers of the Company either severally or jointly with any person nor any trade receivables are due from firms or private companies respectively in which any director is a director, a partner or a 2.) Trade receivables are non interest bearing and are generally on terms of 30 to 90 days.

 3) Trade receivables are given as security for borrowings as disclosed under Note 12 (b).

As at March 31, 2025

Unbilled	Not due	Outst	anding for following p	eriods from due	date of paymer	•	Rs in Lakhs
-	363.13	Less than 6 Months	6 Months - 1 year	1-2 years	2-3 years	More than 3	Total
	505.15		•	6.23		vears -	369.36
	28						505.50
-		1/2					7
			•	5	2		
	20	-	•	949	1721		
	363.13						100
	Unbilled Dues	Dues Not due - 363.13	Dues Not due Less than 6 Months - 363.13	Dues Not due Less than 6 Months 6 Months - 1 year 363.13	Dues Not due Less than 6 Months 6 Months - 1 year 1-2 years	Dues Not due Less than 6 Months 6 Months - 1 year 1-2 years 2-3 years 363.13 6.23 6.23	Dues Not due Less than 6 Months 6 Months - 1 year 1-2 years 2-3 years More than 3 years - 6.23 years - 6.23 years - 6.23 years - 6.24 years - 6.25 y

Particulars	Unbilled	Not due	Outst	anding for following p	eriods from due	date of paymer	nt	Rs in Lak
i) Undisputed Trade receivables - considered good	lyne -	THE PARTY	Less than 6 Months	6 Months - 1 year	1-2 years	2-3 years	More than 3	Total
Undisputed Trade Receivables - which have significant		250.81	324.08	-			vears	
rease in credit risk	20							574.8
) Undisputed Trade receivables - credit impaired	_	-	-	2				
Disputed Trade Receivables considered good	- J		2				34	-
Disputed Trade Receivables - which have significant			-			-		_
rease in credit risk						~	2.5	-
Disputed Trade receivables - credit impaired			5-2					
Total	-				-			227
Total		250.81	324.09	7.4				
		230.01	324.08			STATE OF STREET		57

6 (c) Loans - Current

Particulars	As at	Rs in Lakhs
(Unsecured, considered good unless otherwise stated) Loans to employees		March 31, 2024
oans to related parties (refer note 29)	0.23	0.27
Total Loans		245.00
	0.23	245.27

Notes:

1) No loans are due from directors or promotors of the Company either severally or jointly with any person.

2) Disclosures pursuant to section 186(4) of the Companies Act, 2013.

Details of Loan Given			
Name of the Company	Purpose	As at March 31, 2025	As at
Asence Pharma Private Limited	Ganaral Products		March 31, 2024
Total	General Business Purpose	*	245.00
Loans or Advances in the			245.00

Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties either severally or jointly Repayable on demand

		March 31, 2024		
loan or advance in the nature of loan outstanding	the total Loans and Advances in the nature	Amount of loan or advance in the nature of loan	Percentage to the total Loans and Advances	
		•		
	1070	_	100	
	•			
-	0.00%	245.00	22.7	
-	0.00%	245.00	99.89% 99.89%	
	Amount of loan or advance in the nature of loan outstanding	loan or the total advance in the Loans and nature of loan outstanding (Rs. In Lakhs) of loans	Amount of Percentage to Ioan or the total advance in the Loans and nature of Ioan Advances outstanding in the nature (Rs. In Lakhs) of Ioans	



	March 31, 2025	As at March 31, 2024
Cash on hand		
Balance with Bank	1.24	0.79
In Current accounts	72.38	4.09
Total cash and cash equivalents	73.62	4.88
6 (e) Other bank balances	-	4.00
Particulars	As at	Rs in Lakhs
raticulars and the second seco	March 31, 2025	As at March 31, 2024
Bank Deposits with original maturity of more than three months but less than 12 months Bank Deposits lodged with Excise Department	100.00 1.00	306.29 1.00
Total other bank balances	101.00	307.29
6 (f) Other financial assets		307.29
Particulars		Rs in Lakhs
	As at March 31, 2025	As at
Unsecured, considered good unless otherwise stated) Non-current	Pitti 51, 2025	March 31, 2024
Security deposits	22.89	
Bank Deposits lodged with Excise Department		22.89
Total	1.00 23.89	22.89
Current Accrued Interest	20,02	22.03
	3.55	38.28
Total	3.55	38.28

6 (g) Financial Assets by category

Particulars	FVOCI	COST	A decision to a	Rs in Lakhs
March 31, 2025		COST	Amortised Cost	TOTAL
Investments				
- Equity Shares	6.50	470.74		
Trade Receivables	6.30	479.21		485.71
Loans			369.36	369.36
Cash & Bank balances	6		0.23	0.23
Other financial assets			174.62	174.62
		-	27.44	27.44
Total Financial Assets	6.50			
HE WAS CONTRACTED TO THE PARTY OF THE PARTY	0.30	479.21	571.65	1057.36
March 31, 2024				
Investments				
- Equity Shares	6.50	223 77		
Trade Receivables	6.50	359.19		365.69
Loans	-	-	574.89	574.89
Cash & Bank balances	*	27	245.27	245.27
Other financial assets	5	*	312.17	312.17
Other Intericial assets	발 	7	61.17	61.17
Total Financial Assets	6.50	359.19	1,193,50	1559.19

For Financial instruments risk management objectives and policies, refer Note 35 Fair value disclosure for financial assets and liabilities are in Note 33 and fair value hierarchy disclosures are in Note 34

Note 7 : Other assets

Particulars Particulars	As at	Rs in Lakhs As at
(Unsecured, considered good unless otherwise stated)	March 31, 2025	March 31, 2024
Non-current		
	•	-
Current		
Advance recoverable in cash or kind		
- to related parties (Refer Note 29)	F22.0F	
- to others	533.05	363.89
Prepaid expenses	9.67	2.50
	6.98	5.60
Balance with Government Authorities (Refer Note No. 1 below)	0.04	1.61
Amount paid under protest	1.44	1.44
	551.18	375.04
Total	551.18	375.04
Notes:	331.16	3/5.04

Notes:

1) Balance with Government Authorities mainly consist of input credit.

2) Other current assets are given as security for borrowings as disclosed under Note 12(a).

3) No advances are due from directors or promotors of the Company either severally or jointly with any person nor any advances are due from firms or private companies respectively in which any director is director, partner or a member.

Synbiotics Limited
CIN: U24232G31960PLC000992
Notes to the Financial Statements
Note 8: Inventories (At lower of cost and net realisable value)

Particulars	As at March 31, 2025	Rs in Lakhs As at March 31, 2024
Finished goods	156.61	Security of
Raw Material	133.28	62.39 26.05
Work in progress Stores and Spares	40.32	98.89
Packing materials	20.61	22.26
Total	4.84	5.52
Total	355.66	215.11

Inventories are given as security for borrowings as disclosed under Note 12(a)
 Inventory write downs are accounted, considering the nature of inventory, ageing and net realisable value for Rs. 152.94 Lakhs (March 31,2024 Nii).

The changes in write downs are recognised as an expense in the Statement of Profit and Loss.

Note 9 : Current Tax Assets

Particulars	As at March 31, 2025	Rs in Lakh As at March 31, 2024
Tax Paid in Advance (Net of Provision)	25	9,00
Total		9.00



Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 10: Equity share capital

	No. of shares	As at March 31, 2025		s at 31, 2024
	ite. of shares	Rs in Lakhs	No. of shares	Rs in Lakhs
Authorised share capital				THE EURIS
Equity shares of Rs. 1000 each				
(March 31, 2024 Rs. 1000 each)	1,25,000	1,250.00	1,25,000	1,250.00
Issued and subscribed				
Equity shares of Rs.1000/- each				
(March 31, 2024 Rs. 1000 each)	1,20,446	889.46	1,20,446	889.46
Subscribed and partly paid up				
quity shares of Rs.1000 each, Rs. 100 paid up				
March 31, 2024 Rs. 1000 each, Rs 100 paid up)	35,000	35.00	35,000	35.00
Subscribed and fully paid up				
quity shares of Rs.1000/- each fully paid				
March 31, 2024: Rs. 1000 each)	85,446	854.46	85,446	854.46
	1,20,446	889.46	1,20,446	889.46

10.1. Reconciliation of shares outstanding at the beginning and at the end of the Reporting period

Particulars	As a March 31	As at March 31, 2024		
At the beginning of the period	No. of shares	Rs in Lakhs	No. of shares	
Add: Issue of Share Capital	1,20,446	889.46	1,20,446	Rs in Lakhs
Outstanding at the end of the period	•	-	1,20,440	889.46
	1,20,446	889.46	1,20,446	889.46

10.2. Rights, preferences and restrictions attached to the equity shares

The Company has one class of shares referred to as equity shares having a par value of Rs. 1000 each. Each shareholder is entitled to one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all

10.3. Shares Held by Holding Company

Name of the Shareholder	As at March 31, 2025		As at March 31, 2024	
sence Pharma Private Limited	No. of shares	% of shareholding		% of shareholding
0.4. Number of Shares held by each shareholder hald	1,20,446	100.00%	1,20,446	

10.4. Number of Shares held by each shareholder holding more than 5% Shares in the Company

		mpany		
Name of the Shareholder	As at March 31, 2025		As at March 31, 2024	
Asence Pharma Private Limited	No. of shares %	of shareholding No.		% of shareholding
	1,20,446	100.00%	1,20,446	100.00%

10.5. Shares Held by Promoters

Particulars	As at March 31, 2025			As at March 31, 2024			
	No. of shares	% of Total Shares	% Change During the year			% Change During the year	
Asence Pharma Private Limited	1,20,446	100.00%	5	1,20,446	100.00%		

10.6. Objective, policy and procedure of capital management, refer Note 36



Note 11 : Other Equity

Note 11.1 Reserves & Surplus	As at March 31, 2025	As at March 31, 2024
Securities premium Balance as per last financial statements		,
Retained Earnings / Surplus in statement of Profit/loss Balance as per last financial statements	869.50	869.50
Add: Profit/(Loss) for the year Add/(Less): OCI for the year Balance at the end of the year	830.35 (402.54) 	872.43 (37.27
otal reserves & surplus	428.27	(4.81 830.35
otal Other equity	1,297.77	1,699.85
The description of the nature and purpose of each reserve within equity is as follow	1,297.77	1,699.85

Securities premium
 Securities premium is created due to premium on issue of shares. These reserve is utilised in accordance with the provisions of the Companies Act.

Note 12 : Financial liabilities

12 (a) Borrowings

Particulars	As at March 31, 2025	Rs in Lakh As at
Long-term Borrowings (Refer Note 1(a) below) Secured		March 31, 2024
Term loan from Banks		
Total long-term borrowings	138.68	200
Short-torm Review	138.68	205.97
Short-term Borrowings (Refer Note 1(b) and 2 below) Secured	250100	205.97
Current maturity of long term borrowings		
onsecured loan	73.37	
From Related Parties (Refer note 29) Secured		39.28
	30.00	30.00
Working Capital Loans repayable on demand from Banks otal short-term borrowings		30.00
	359.89	333.83
otal borrowings	463.26	403.11
lotes:	601.94	609.08
1. Secured Borrowings (a) Long term		303.08

Particulars	Rs in Lakhs	Rate of Interest		
Term Loan	212.05	8.90%	Security Secured against Property, Plant & Equipment of the Company, i.e. Land & building and Plant and Machineries. Additionally secured by Corporate guarantee of Ambala South South	Repayment terms
b) Short term borro	wings		Machineries. Additionally secured by Corporate guarantee of Ambalal Sarabhai Enterprises Limited.	Reyable in monthly instalments ranging between 32 to 45
Particulars	Rs in Lakhs	Rate of Interest	Cocurb.	

	ks in Lakhs	Rate of Interest		
Working Capital Loans	359.89	8.90%		Repayment terms
2. Unsecured Borrowings (a) Short Term	i		guarantee of Ambalal Sarabhai Enterprises Limited.	NA

Particulars	Rs in Lakhs	Rate of Interest		
Short term borrowings	30.00	8.00%	Security	
12 (b) Trade pavables	5		NA	Repayment terms
The same of the sa				Repayable on demand

Particulars		P-1-1
Current Trade Payables (Refer Notes Below)	As at March 31, 2025	Rs in Lakhs As at March 31, 2024
Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises Total		
Total Total	48.36 75.27	24.57 67.0
ote:	123.63	91.6

Note:
The Company has received intimations from suppliers regarding their status under the Micro, Small and Medium Enterprise Development (MSMED) Act, 2006 and hence disclosures as required under Section 22 of The Micro, Small and Medium Enterprise Development (MSMED) Act, 2006 are as mentioned below:

(a) the principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year; (ii) Interest	As at March 31, 2025	As at March 31, 2024
b) the amount of interest and but a	48.36	24.57
006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	5	•
 the amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during ne year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006; the amount of interest accrued and remaining unpaid at the end of each accounting year; and 	(a)	
) the amount of further interest remaining unpaid at the end of each accounting year; and tually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium	*	•



Trade Payables ageing schedule:

	agemy	Schedule
As at March 31.	2025	

Particulars	Not Due -	ot Due Outstanding for following periods from due date of Payment					
MSME		Less than 1 year	1-2 years	1-2 years	2-3 years	More than 3	Total
Others	48.36	2				years	
Disputed dues - MSME	6 1 97	67.71		•	•		48.36
Disputed dues - Others	8 3 2	779257		<u>s</u> :		5.26	72.97
Inbilled dues	2.20	7/25			(#)	-	-
Total	2.30				•		-
	50.66	67.71	0.00	0.00	0.00		2.30
As at March 31, 2024					0.00	5.26	123.63

As at March 31, 20

Particulars	Not Due -	Outstanding for following periods from due date of Payment					
MSME		Less than 1 year	1-2 years	1-2 years	2-3 years	More than 3	Total
Others	24.58	2				years	
Disputed dues - MSME	1.52	61.79		-			24.58
Disputed dues - Others		=	3=10	2		5.26	67.0
Inbilled dues		<u>=</u>		-	5	-	-
Total	24.50			-			-
	24.58	61.79	0.00	0.00	•		
				0.00	0.00	5.26	91.6

12 (c) Other financial liabilities - Current

Particulars	As at	Rs in Lakhs
Pavable to employees	March 31, 2025	As at March 31, 2024
Payable to Directors (Refer note 29) other Liabilities	23.77 3.75	33.75
otal	111.00	4.63
	138.52	38.38

12(d): Financial Liabilities by category

Particulars	THE PARTY OF THE P			Rs in Lakhs
	FVTPL	FVOCI	Amortised Cost	Total
March 31, 2025				·otal
Borrowings				
Lease liabilities	•	-	601.94	2.5
Trade payables	(4)	-	79.73	601.94
Payable to employees	•		123.63	79.73
Payable to Directors	-	-	23.77	123.63
Total Financial liabilities		-	3.75	23.77
		9=0	832.82	3.75
farch 31, 2024			832.82	832.82
Sorrowings				
ease liabilities			500 00	
rade payables	<u> </u>		609.08	609.08
ayable to employees	8	-	86.05	86.05
avable to Directors			91.63	91.63
otal Financial liabilities	Li Li		33.75	33.75
		- 2	4.63	4.63
or Financial instruments viets			825.14	825.14

For Financial instruments risk management objectives and policies, refer Note 35 Fair value disclosure for financial assets and liabilities are in Note 33 and fair value hierarchy disclosures are in Note 34

Note 13: Provisions

Particulars	As at March 31, 2025	As at March 31, 2024
Long-term		March 31, 2024
Provision for employee benefits (Refer Note 28) Provision for leave encashment		
Provision for Gratuity	26.70 0.47	24.69 3.33
Short-term	27.17	28.02
Provision for employee benefits (Refer Note 28) Provision for leave encashment		20.02
rovision for Gratuity	4.33	9.41
	12.89	14.24
Total	17.22	23.65
	44.39	51.67

Note 14: Other current liabilities

Particulars	As at March 31, 2025	As at March 31, 2024
Current	See all the control of the control o	PHICH 31, 2024
Advance from Related parties (refer note 29)		
Advance from customers	8.91	
Statutory dues including provident fund and tax deducted at source etc.	4.00 39.46	4.00 75.57
Total		/5.5/
	52.37	79.57

Note 14A : Current tax liability (Net)

Particulars	As at March 31, 2025	As at March 31, 2024
Provision for Taxation (Net of Advance Tax)	11.02	-
A	11.02	



Note 15: Revenue from operations

Particulars		Rs in Lakh
	Year Ended	Year Ended
Sale of products	March 31, 2025	March 31, 2024
odic of products	1 401 05	
Total	1,491.96	1,420.42
	1,491.96	
I. Disaggregation of Revenue from Contracts with Customers	=/152150	1,420.42
Particulars		
raiticulars	Year Ended	Year Ended
A. Revenue based on Geography	March 31, 2025	March 31, 2024
i. Domestic		March 31, 2024
i. Export	1,491.96	
	-, 10 2130	1,420.42
	1,491.96	
3. Revenue based on Business Segment	-, .52.50	1,420.42
Pharmaceutical Products		
Harmaceutical Products	1,491.96	
	1,491.96	1,420.42
I. Reconciliation of Revenue from Operation with Contract Price		
Particulars		
	Year Ended	Year Ended
A DATA SERVICIO DE LA COMPANSIONE DEL COMPANSIONE DE LA COMPANSION	March 31, 2025	March 31, 2024
ontract Price		
ess: Sales Return	1,491.96	1,489.72
otal Revenue from Operations	-	(69.30)
	1,491.96	1,420.42

Note 16: Other income

Particulars	Year Ended March 31, 2025	Rs in Lakhs Year Ended March 31, 2024
Interest income on financial assets recognised at amortised cost		
Sundry balance written back (Net)	28.53	47.86
Royalty income	•	
Dividend income	24.16	14.71
Service charges recovered	0.98	18.11
Rental income	111.08	0.98
Guarantee commission	142.56	75.87
interest on income tax refund	-	142.56
Profit on sale of property, plant and equipment	1.35	4.54
discellaneous income		1.56
otal	3.44	5.24
	312.10	7.54 318.97

Note 17 : Cost of material consumed

Year Ended March 31, 2025	Rs in Lakhs Year Ended March 31, 2024
31.57 ————————————————————————————————————	47.57
436.74 138.12	130.40 177.97 31.57
	March 31, 2025 31.57 405.17 436.74

Note 18: Changes in inventories of Finished goods and Work-in-progress

Particulars	Year Ended March 31, 2025	Rs in Lakh Year Ended March 31, 2024
Stock at the end of the year Finished goods		1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Work-in-Progress	156.61	62.39
Control Control of Con	40.32	98.89
Stock at the beginning of the year Finished goods		30.03
Work-in-Progress	62.39	140.06
Total	98.89	129.57
	(35.65)	108.35

Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements Note 19: Employee benefits expense

Particulars	Year Ended March 31, 2025	Rs in Lakhs Year Ended March 31, 2024
Salaries, wages, gratuity, bonus, commission, etc. Contribution to provident and other funds (Refer Note 28) Welfare and training expenses Director Remuneration (Refer Note 29)	253.09 13.15 24.55	251.28 12.23
Total	93.59 384.38	24.08 76.28 363.87

Note 20 : Finance costs

Particulars	Year Ended March 31, 2025	Rs in Lakhs Year Ended March 31, 2024
Interest expense		1-laich 31, 2024
Term Loans		
Working Capital Loans	23.35	20.44
Lease Liabilities (Refer Note 31)	27.44	20.14
Other borrowing cost	8.64	28.19
Total	9.80	7.26
	69.23	8.51 64.10

Note 21: Depreciation and amortization expense

Particulars	Year Ended March 31, 2025	Rs in Lakhs Year Ended March 31, 2024
Depreciation on Property, Plant and Equipment (Refer Note 5) Depreciation on Right-of-Use assets (Refer Note 31) Total	95.19 30.74	92.10 25.85
	125.93	117.95

Note 22: Other expenses

Particulars	Year Ended	Rs in Lakhs
	March 31, 2025	March 31, 2024
Power and fuel		
Factory Oveheads	382.38	354.96
Legal & Professional charges	298.09	251.12
CSR Expenses (Refer Note 32)	130.06	142.32
Stores consumed		12.00
Insurance	38.98	39.00
Processing charges	9.43	8.80
ETP Expenses	46.97	32.48
Hire Charges	15.97	13.55
Rates and taxes	24.58	26.15
Repairs:	7.65	6.46
To Building		0.40
To Machineries	24.55	24.19
To Others	54.07	44.38
Distribution Expenses	11.68	16.33
Directors' sitting fees (Refer Note 29)	7.00	4.45
Conveyance & Travelling expense	0.12	0.21
enalties	4.19	7.85
uditor's remuneration (Refer Note a below)	2.73	0.05
liscellaneous expenses	4.40	4.11
oss on Reassessment of Lease Liability	14.51	
undry balance written back (Net)	5.28	9.11
otal	0.11	
	1,082.75	997.52

Note:

a. Break up of Auditor's Remuneration

Particulars	Year Ended	Year Ended
Payment to Auditors as :	March 31, 2025	March 31, 2024
Auditors		27 2027
For tax audit	1.90	1.70
For other certification work	0.69	0.69
For reimbursement of expenses	0.75	0.73
Total	1.06	0.99
	4.40	4.11

Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 23: Exceptional Item

Particulars	Year Ended March 31, 2025	Rs in Lakh Year Ended March 31, 2024
Settlement of Litigation	240.00	-
Total	240.00	



Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

B) Deferred tax

Particulars	Balance Sheet	Statement of Profit & Loss and Other Comprehensive Income	Balance Sheet	Rs in Lakhs Statement of Profit & Loss and Other Comprehensive Income
	As at March 31, 2025	Year Ended March 31, 2025	As at March 31, 2024	Year Ended March 31, 2024
Accelerated depreciation for tax purposes Expenditure allowable on payment basis Carry forward losses Impact of fair valuation of Equity Instrument Implementation of Ind AS 116	(167.01) 11.92 -	0.40 1.80 31.31	(166.61) 13.72 31.31	
Net deferred tax assets/(liabilities) The Company offsets tax assets and liabilities if and only	3.05 (152.04)	(1.96) 31.55	1.09	0.11

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

The Company has unused carried forward losses of Rs. 461.94 Lakhs as at March 31, 2025 (March 31, 2024: Rs. 124.39 Lakhs). Out of the same, tax credits on losses Rs. Nil (March 31, 2024: Rs. 31.31 Lakhs) have been recognized.

Reconciliation of Deferred Tax Assets/(Liabilities)

Particulars Opening balance as at April 1	Year Ended March 31, 2025	Rs in Lakhs Year Ended March 31, 2024
Deferred Tax income/(expense) during the period recognised in profit or loss	(120.49)	(143.64)
Deferred Tax income/(expense) during the period recognised in OCI Closing balance as at March 31	(31.39)	21.53 1.62
	(152.04)	(120.49)



CIN: U24232GJ1960PLC000992 **Notes to the Financial Statements**

Note 24: Income Tax

The major component of income tax expense:

Particulars	Year Ended	Rs in Lakhs Year Ended
Statement of Profit & Loss	March 31, 2025	March 31, 2024
Current Tax		
Current income tax		
Short provision related to earlier years		U -9
Deferred Tax	9.95	€ 02
Deferred tax charge/(credit)	31.39	(21.53)
Income tax expense reported in the statement of standalone profit & loss	41.34	(21.53)

OCI Section

Particulars Statement of Other and I also a second and I also a s	Year Ended March 31, 2025	Year Ended March 31, 2024
Statement of Other comprehensive income (OCI) Current tax	•	1111 011 02/ 2024
Deferred tax charge/(credit)	-	-
	(0.16)	1.62
Deferred tax charged to OCI	(0.16)	1.62

Reconciliation of tax expense and the accounting profit multiplied by domestic tax rate:

A) Current tax

Particulars	Year Ended March 31, 2025	Year Ended March 31, 2024
Accounting profit/(loss) before tax	(361.20)	(58.80)
Tax Rate	25.168%	25.168%
Current Tax Expenses on Profit before tax at the enacted income tax rate in India Adjustments	(90.91)	(14.80)
Unused tax losses Short provision related to earlier years	116.26	31.31
Expenditure not deductible for tax/not liable to tax Others	9.95 1.19	#0 F)
At the effective income tax	4.85	(38.04)
Effective Income Tax Rate %	41.34	(21.53)



CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 25: Contingent liabilities

Particulars		Rs in Lakhs
Particulars	As at March 31,2025	As at March 31,2024
Contingent liabilities not provided for		
(a) Disputed demands in respect of		
(i) ESI Damages	81.35	
(ii) Income tax		81.35
(iii) GST	120.16	120.16
(iv) PF Damages	14.45	14.45
h) Guarantoe given by the Game	20.95	20.95
b) Guarantee given by the Company on behalf of other company	1.88	1.88

Notes:

- (a) It is not practicable for the Company to estimate the timing of cash outflows, if any, in respect of the pending resolution of the respective proceedings mentioned in (a) above
- (b) The Company does not expect any reimbursements in respect of the above Contingent liabilities.
- (c) The Company believes that the ultimate outcome of these proceedings will not have a material adverse effect on the Company's financial position and results of operations.

Note 26: Capital commitment and other commitments

		Rs in Lakhs
Particulars	As at March 31,2025	As at March 31,2024
Capital commitments		1
Estimated amount of Contracts remaining to be		
executed on capital account and not provided for		340
Other commitments		
	-	1221
Total		



CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 27: Segment Reporting

The chief operational decision maker monitors the operating results of its Business segment separately for the purpose of making decision about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the financial statements. Operating segment have been identified on the basis of nature of products and other quantitative criteria specified in the Ind AS 108. Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") of the

The Company is primarily engaged in the business of manufacturing of Pharmaceuticals product , which in the context of Indian Accounting Standard 108 on Segment Reporting, constitutes a single reportable primary (business) segment.

Geographical segment

Geographical segment is considered based on sales within India and rest of the world.

Particulars	Year Ended March 31, 2025	Rs. In Lakhs
Segment Revenue*	Platett 51, 2025	March 31, 2024
a) In India b) Rest of the world	1,491.96	1,420.42
Total Sales		-
Carrying Cost of Segment Assets**	1,491.96	1,420.42
a) In India		-
b) Rest of the world	3,390.87	3,666.18
Total	(*)	
Carrying Cost of Segment Non Current Assets @	3,390.87	3,666.18
a) In India		
b) Rest of the world	1,426.67	1,507.84
Total		<u>10</u>
* Based on location of Customers	1,426.67	1,507.84

Based on location of Customers

Information about major customers:

Considering the nature of business of company in which it operates, the company deals with various customers including multiple geographics. There are 2 customers contributing Rs. 1172.87 Lakhs (March 31, 2024 : 1 customers, Rs. 802.55 Lakhs) of the total revenue of the Company from domestic sales.



^{**} Based on location of Assets

[@] Excluding Financial Assets and Deferred Tax Assets

Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 28: Disclosure pursuant to Employee benefits

Defined Contribution Plans
Amount of Rs. 13.15 Lakhs (March 31, 2024; Rs.12.23 Lakhs) is recognised as expenses and included in Note No. 19 "Employee benefits expenses"
Particulars
Particulars
March 31,2025
March 31,2024 5.89 7.26 **13.15** Provident Fund Pension Fund

Defined Benefit Plans
The company has following post employment benefits which are in the nature of defined benefit plans:

Gratuity

The Company provides for gratuity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement/termination is the employees last drawn salary per month of gratuity plan is a funded plan administered by the Company.

Liabilities with regard to the Gratuity Plan are determined by actuarial valuation, performed by an independent actuary, at each Balance Sheet date using the projected unit credit method. The Company fully contributes all ascertained liabilities to the LIC Insurance Policy.

The Company recognizes the net obligation of a defined benefit plan in its Balance Sheet as an asset or liability. Gains and losses through remeasurements of the net defined benefit liability/(asset) are recognized in other comprehensive income and are not reclassified to profit or loss in excess of the yields computed by applying the discount rate used to measure the defined benefit obligations recognized in other comprehensive income.

		Gratuity cost char	Gratuity cost charged to statement of profit and loss	of profit and loss		Remeasi	urement (gains)	Remeasurement (gains)/losses in other comprehensive income	mprehensive inc	come		Rs. In Lakhs
2024-25	April 1, 2024	Service cost	Net interest expense	Sub-total included in statement of profit and loss (Note 19)	Benefit paid	Return on plan assets (excluding amounts included in net interest	Actuarial changes arising from changes in demonstration	Actuarial changes arising from changes in financial	Experience adjustments	Sub-total included in OCI	Contributions by employer	March 31, 2025
Gratuity Defined benefit obligation Fair value of plan assets	74.92 (57.35)	3.75	5.41 (4.14)	9.16	(31.53)	(esuedxe	assumptions	assumptions 1.49	(2.39)	06.0		
Total benefit liability	17.57	3.75	1.27	5.02		0.28		9	•	0.28	(8.60)	(38.29)
March 31, 2024: Changes in defined benefit obligation and plan assets	ned benefit obligation and plan	assets			1000	0.28		1.49	(2,39)	(0.62)	(8.60)	13.36
		Gratuity cost char	Gratuity cost charged to statement of profit and loss	f profit and loss		Remeasu	rement (gains)/	Remeasurement (gains)/losses in other comprehensive income	norehensive inc	ome		Rs. In Lakhs
2023-24	April 1, 2023	Service cost	Net interest expense	Sub-total included in statement of profit and loss (Note 19)	Benefit paid	Return on plan assets (excluding amounts included in net interest expense)	Actuarial changes arising from changes in demographic	Actuarial changes arising from changes in financial	Experience adjustments i	Sub-total included in OCI	Contributions by employer	March 31, 2024
Gratuity Defined benefit obligation Fair value of plan assets	81.20 (74.58)	4.02	6.11 (5.61)	10.13	(22.17)		assumptions	assumptions 0.97	4.79	5.76		24.03
Total benefit liability	6.62	4.02	0			000		•	•17	0.67		(57 72)

0.97

CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

The major categories of plan assets of the fair value of the total plan assets of Gratuity are as follows:

Particulars	Year Ended March 31, 2025	Year Ended
Insurance company Products	100%	March 31, 2024
(%) of total plan assets	2000000	100%
	100%	100%

The principal assumptions used in determining above defined benefit obligations for the company's plans are shown below:

	b the company's pla	below:			
Particulars	Year Ended March 31 ,2025	Year Ended March 31 ,2024			
Discount rate Future salary increase Attrition rate	6.81% 6.00% 2.00%	7.22% 6.00% 2.00%			
Mortality rate during employment	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)			

A quantitative sensitivity analysis for significant assumption is as shown below:

Particulars Gratuity	Sensitivity level	Year Ended March 31 ,2025	Year Ended
			March 31 ,2024
Discount rate	1% increase	Ş	
	1% decrease	(3.46)	(3.05
	1% increase	4.10	3.59
	1% decrease	3.62	3.02
Attrition rate		(3.05)	
recition rate	1% increase	0.24	(2.55
	1% decrease	12000000	0.37
		(0.28)	(0.42

The followings are the expected future benefit payments for the defined benefit plan:

Particulars	Year Ended	Year Ended
Gratuity	March 31,2025	March 31,2024
Within the next 12 months (next annual reporting period) Between 2 and 5 years Beyond 5 years Total expected payments	6.04 30.10 68.82	31.26 29.32 65.31
rotal expected payments	104.96	125.89

Weighted average duration of defined plan obligation (based on discounted cash flows)

Particulars Gratuity	Year Ended March 31,2025	Year Ended March 31,2024
	5 Years	5 Year

C Leave encashment

Salaries and Wages includes following amounts towards provision made as per actuarial valuation in respect of accumulated leave encashment/compensated absences.

Particulars	Year Ended March 31,2025	Year Ended March 31,2024
Leave encashment	6.45	13.68
	6.45	13.68



CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 29: Related Party Transactions

As per the Indian Accounting Standard on "Related Party Disclosures" (Ind AS 24), the related parties of the Company are as follows :

(a) Name of Related Parties and Nature of Relationship:

r. No		
	Ambalal Sarabhai Enterprises Ltd	Description of relationship
2	Asence Pharma Pvt Ltd	Ultimate Holding Company
3	Systronics (I) Limited	Holding Company
4	Cosara Diagnostics Private Limited	Fellow Subsidiary Company
5	Ambalal Sarabhai Foundation	Joint Venture
1	Key Management Personnel Mr. Mohal K Sarabhai	Trust under the control of KMF
2	Mr. Rajiv M Dhru	Non Executive Director
3	Mr. Anurag Mehta	Director
4	Mr. Mayur Swadia	Whole time Director
occes.	The Flayer Swadia	Independent Director



Particulars	Holding Company & Ultimate Holding	Fellow	Joint ventures	Key Managerial	Rs in Lakh
Sales of Goods and Materials March 31, 2025	Company	Subsidiaries	Joint Ventures	Personnel	Trust under the control of KMP
March 31, 2024	711.07	-	ASSESS OF STREET		S. O. KIND
100 000 100 000 100 100 100 100 100 100	802.55	19	1	=	(4)
Purchase of Goods and Materials March 31, 2025			-	-	-
farch 31, 2024	- 1	0.88			
	- 1	-		•	92
Receiving of Services-Shared services	1 1	1		-	
larch 31, 2025	1	4			
larch 31, 2024	86.41	-	-		
SR Donation given	85.69	-	-		*
arch 31, 2025			1		*
arch 31, 2024	8.0	-	2		
andering of Samilar P	-		÷	5	
endering of Services-Royalty arch 31, 2025				₹(12.00
arch 31, 2024	24.16				
har aver-	18.11	-			(+)
ther expenses arch 31, 2025			5.55		3 7
irch 31, 2024	1 - 1				
	- 1	2	-	1.92	- 1
endering of Services-Rent arch 31, 2025				3.36	-
arch 31, 2025		_			
SAS SESSION COMMISSION	21		142.56 142.56	~	
endering of Services-Others	1		142.56	-	
rch 31, 2025 rch 31, 2024	1.54	199	1550497.0889.0		
		-	111.08		12
ectors' Sitting fees			75.87	29	
ch 31, 2025 ch 31, 2024	1 2 1				
31, 2024	- 1			0.12	-
fessional fees		-88		0.21	2
th 31, 2025 th 31, 2024		10			ŊIII
DCD-2006420 (200762000)		-	•	2.06	_
rantee Commission received		-	-	1.80	1
h 31, 2025 h 31, 2024					
		4.54		9	
rantee Commission given		4.54	-	2	
ch 31, 2025	7.00				
h 31, 2024	7.80 6.36	(-)	2	-	
uneration	0.30		-		
31, 2025					
h 31, 2024		120	(-	93.59	
est received on loan	- 1	-	-	76.28	- 1
31, 2025				47 (977)	
31, 2024	13.97				
est paid on loan	-				
31, 2025					
31, 2024	-	2		2.40	
nce received		*		2.40	-
31, 2025					(2)
31, 2024	8.91	(17)	2		
Given // Benefit	- 1	-	-		
Given/(Repaid) 31, 2025	1			Ē:	-
31, 2024	- 1	-			
	- 1	-	2	-	-
aken/(Repayment of Loan) 31, 2025				-	-
11, 2024	(245.00)	2			
	-	-	-	-	-
ments in equity shares					5-
1, 2024	©	-:	120.02		dt.
		5-25	120.02	-	(See all



Balances

Particulars	Holding Company &				Rs in Laki
	Ultimate Holding	Fellow	Joint ventures	Key Managerial	
Investment	Company	Subsidiaries	Joint ventures	Personnel and Non	Trust under the
March 31, 2025				Executive Directors	control of KMP
March 31, 2024	1721		W. W. W. W. W. W. W.	4100-0000000000000000000000000000000000	
	12		479.21	-	
Possinski i		97	359.19		*
Receivable in respect of Current Assets March 31, 2025	1				
Aprels 31, 2025	1			1	
March 31, 2024	(2.2)		533.05	-	
		.= 1	363.89		
Pavable in respect of Current Liabilities	1 1	1	505.05	-	
narch 31, 2025	1			4	
March 31, 2024		21		4.5	
March 31, 2023		2	1010	N/V	
	- 1	8	-	-	2
rade and Other Receivable		- 1	-	-	2
farch 31, 2025	1	- 1	1		-
larch 31, 2024	272.99	- 1		7	
101011 31, 2024	540.32	*	2	_	
	340.32	= = =	-	- 1	1.5
rade and Other Payable	1	1	7	5.	U.7
larch 31, 2025	929920	-	1	1	
arch 31, 2024	8.91	92			
		-		3.75	4
orrowing	I I	-	5.	4.63	
arch 31, 2025	1		1		
arch 31, 2024	- 1				
	- 1	170	8-1	30.00	
pan Given/(Repaid)	1		-	30.00	•
arch 31, 2025		1	17		-
arch 31, 2024		1	1	11	
arch 31, 2024	245.00	*		-	1
	245.00	-	23 11	- 1	*
arantee	11			-	
rch 31, 2025					
rch 31, 2024	571.94	2			
	579.08			- 1	2

c Terms and conditions of transactions with related parties

1) Transaction entered into with related party are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances other than loan given & taken at 2011 to 1012 to 2) Loans in INR taken from the related party carries interest rate of 8% (March 31, 2024 : 8%)

d Commitments with related parties

The Company has not provided any commitment to the related party as at March 31, 2025 : Rs Nil (March 31, 2024: Rs. Nil)



Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 30 : Earnings per share

Particulars		Year Ended March 31, 2025	Year Ended March 31, 2024
Loss attributable to ordinary equity holders	Rs. In Lakhs	(402.54)	(37.27)
Total no. of equity shares at the end of the year	Nos.	1,20,446	1,20,446
Weighted average number of equity shares Nominal value of equity shares Basic and diluted earnings per share	In Rs. In Rs.	88,946 1,000 (452.57)	88,946 1,000 (41.90)



CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 31: Leases

The Company has taken factory land on lease period of 2 to 5 years. Disclosures as per Ind AS 116 - Leases

Changes in the carrying value of right of use assets

Particulars	Year Ended	Rs in Lakhs Year Ended
Balance at the beginning of the year	March 31, 2025	March 31, 2024
Additions	81.72	22.93
Deletions	16.65	84.64
Depreciation (charged to statement of profit and loss)	-	-
Balance at the end of the year	(30.74)	(25.85)
or the year	67.63	81.72
Movement in Land III and III		01.72

c Movement in lease liabilities

- 10 venicit in lease nabilities		
Particulars	Year Ended	Rs in Lakhs Year Ended
Balance at the beginning of the year	March 31, 2025	March 31, 2024
Additions	86.05	27.70
Deletions	21.93	84.64
Finance cost accrued during the year	<u>=</u>	-
(charged to statement of profit and loss) Payment of lease labilities	8.64	7.26
Balance at the end of the year	(36.89)	(33.55)
or the year	79.73	86.05

Particulars	Year Ended	Rs in Lakhs Year Ended
Less than one year	March 31, 2025	March 31, 2024
One to five years	19.11	33.54
Total	60.62	52.51
	79.73	86.05

The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.



Note 32 : Corporate Social Responsibility (CSR) Activities

Particulars		Rs. In Lakhs
a) Gross amount required to be spent by the Company during the year	As at March 31, 2025	As at March 31, 2024
o) Amount spend during the year (in cash)	-	12.00
i) Construction/ acquisition of any asset	100	
(ii) Contribution to various Trusts / NGOs / Societies /Agencies and utilization		12.00
charcon		12.00
(iii) Expenditure on Administrative Overheads for CSR	S=S	
c) Amount unspent during the year	3 T 3	-
d) Total of previous years shortfall		
e) Reasons for shortfall	-	0.24
f) Details of related party transactions		
Name - Ambalal Sarabhai Foundation		
Relationship - Trust under the control of KMP Amount		
Movement of CSR Provision		12.00
Ralance as per lest financial as a series of the series of		12.00
Balance as per last financial statements Add: Provision made during the year	0.24	0.24
(Less): Utilised during the year	5.21	12.00
Balance at the end of the year		
balance at the end of the year	0.24	(12.00) 0.24



Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 33: Fair value disclosures for financial assets and financial liabilities

Set out below is a comparison, by class, of the carrying amounts and fair value of the company's financial instruments, other than those with carrying amounts that are reasonable approximations of fair values:

		KS. In Lakhs
Particulars	As at	Asat
Financial assets	CZOZ ATC IIDIBIA	Haich 31, 2023 March 31, 2024
Investments measured at FVOCT		
Carrying Amount		
Fair Value	6.50	6.50
Investments measured at cost	6.50	
Carrying Amount	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	
Fair Value	479.21	359.19
))) ;	479.21	
Financial liabilities		
Borrowings		
Carrying Amount		
Fair Value	601.94	609.08

The management assessed that the fair values of cash and cash equivalents, other bank balances, loans trade receivables, other current financial assets, trade payables and other current financial liabilities approximate their carrying amounts largely due to the

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to

The fair value of borrowings and other financial liabilities is calculated by discounting future cash flows using rates currently available for debts on similar terms, credit risk and remaining maturities.

Note 34: Fair value hierarchy

The Company provides the fair value measurement hierarchy of the company's assets and liabilities as below, if any:

Quantitative disclosures fair value measurement hierarchy for financial assets and liabilities as at March 31,2025 and March 31,2024

		Fair	Fair value measurement using	Ks in Lakhs
Particulars	Date of valuation	Quoted prices in active markets	Significant observable inputs	Significant unobservable innute
Assets measured at fair value			(revei 2)	(Level 3)
Investments measured at FVOCI	March 31, 2025	9		
Liabilities measured at fair value	March 31, 2024	(1.6)	E 1	6.50
Borrowings	March 31, 2025 March 31, 2024	9.30	601.94	1
Fair value hierarchy			80.600	

Fair value hierarchy includes financial instruments measured using quoted prices. This includes listed equity instruments that have quoted price. The fair value of all equity Lesvel 1. Level 1 hierarchy includes financial instruments which are traded in the stock exchanges is valued using the closing price as at the reporting period.

Level 2. The fair value of financial instruments that are not traded in an active market (for example, traded bonds, over-the counter derivatives) is determined using valuation techniques which maximize the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities,

There are no transfer between level 1, 2 and 3 during the year. The Company's policy is to recognise transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.

Notes to the Financial Statements CIN: U24232GJ1960PLC000992 Synbiotics Limited

Note 35: Financial instruments risk management objectives and policies

The Company's principal financial liabilities, other than derivatives, comprise borrowings and trade & other payables. The main purpose of these financial liabilities is to finance the company's operations. The company's principal financial assets include Investments, loans given, trade and other receivables and cash & short-term deposits that derive directly

The Company's activities expose it to market risk, credit risk and liquidity risk. In order to minimise any adverse effects on the financial performance of the Company, derivative financial instruments, such as foreign exchange forward contracts, foreign currency option contracts are entered to hedge certain foreign currency exposures. Derivatives are used exclusively for hedging

The Company's risk management is carried out by a Treasury department under policies approved by the Board of directors. Company's treasury identifies, evaluates and hedges financial risks in close co-operation with the Company's operating units. The board provides written principles for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity,

(a) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises two types of risk: interest rate risk and currency risk. Financial instruments affected by market risk include borrowings, deposits, Investments, trade and other receivables, trade and other payables and derivative financial

identify the risk position of the entities. Sensitivity analysis provides an approximate quantification of the exposure in the event that certain specified parameters were to be met under a specific Within the various methodologies to analyse and manage risk, company has implemented a system based on "sensitivity analysis" on symmetric basis. This tool enables the risk managers to set of assumptions. The risk estimates provided here assume:

- a parallel shift of 50-basis points of the interest rate yield curves in all currencies.
- a simultaneous, parallel foreign exchange rates shift in which the INR appreciates / depreciates against all currencies by 2%

The potential economic impact, due to these assumptions, is based on the occurrence of adverse / inverse market conditions and reflects estimated changes resulting from the sensitivity analysis. Actual results that are included in the Statement of profit & loss may differ materially from these estimates due to actual developments in the global financial markets.

The analyses exclude the impact of movements in market variables on: the carrying values of gratuity, pension and other post-retirement obligations and provisions.

The following assumption has been made in calculating the sensitivity analyses:

- The sensitivity of the relevant statement of profit or loss item is the effect of the assumed changes in respective market risks. This is based on the financial assets and financial liabilities held at respective period/year end including the effect of hedge accounting.

Interest rate risk

Interest rate risk arises from the sensitivity of financial assets and liabilities to changes in market rates of interest. The Company has not

hedged its interest rate risk.

As at March 31, 2025, 100% of the Company's Borrowings are at fixed rate of interest (March 31, 2024 : 100%)

Interest rate sensitivity

The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings affected, after the impact of hedge accounting. With all other variables held constant, the company's profit before tax is affected through the impact on floating rate borrowings, as follows:

Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements Rs in Lakhs

Effect on profit before tax		
Particulars	March 31, 2025 Increase in 50 basis points Decrease in 50 basis points	March 31, 2024 Increase in 50 basis points Decrease in 50 basis points

(b) Credit risk

assets. Individual risk limits are set and periodically reviewed on the basis of such information. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and assesses financial reliability of customers and other counterparties, taking into account the financial condition, current economic trends and analysis of historical bad debts and ageing of financial Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. To manage this, the Company periodically from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

Trade receivables

negligible provision for bad and doubtful debts. Therefore, the Company does not expect any material risk on account of non-performance by any of the Company's counterparties. The Company does not have significant concentration of credit risk related to trade receivables. However, 2 customers contribute to more than 10% of outstanding accounts receivable as of March 31, 2025 (1 All trade receivables are subject to credit risk exposure. The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the business. Outstanding customer receivables are regularly monitored and any shipments to major customers are generally covered by letters of credit. The history of trade receivables shows a policies, controls relating to credit approvals and procedures for continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of customer, including the default risk of the industry and country, in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through established customer contribute to more than 10% of outstanding accounts receivable as of March 31, 2024).

Financial instruments and cash deposits

only with approved counterparties who meets the minimum threshold requirements under the counterparty risk assessment process. The Company monitors the ratings, credit spreads and financial strength of its counterparties. Based on its on-going assessment of counterparty risk, the Company adjusts its exposure to various counterparties. The Company's maximum exposure to Credit risk from balances with banks and financial institutions is managed by the Company's treasury department in accordance with the Company's policy. Investments of surplus funds are made credit risk for the components of the Balance sheet as is the carrying amount as disclosed in Note 33.

(c) Liquidity risk

Liquidity risk is the risk that the company may not be able to meet its present and future cash and collateral obligations without incurring unacceptable losses. The company's objective is to, at all maintains adequate sources of financing including bilateral loans, debt and overdraft from both domestic and international banks at an optimised cost. It also enjoys strong access to domestic times maintain optimum levels of liquidity to meet its cash and collateral requirements. The company closely monitors its liquidity position and deploys a robust cash management system. It

The table below summarises the maturity profile of the company's financial liabilities based on contractual undiscounted payments:

Synbiotics Limited CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Less than 1 yengs*			The second secon		CHARLES III CO.
*sgn		1 year to 3 years	3 years to 5	more than 5	Total
*Sgn					
*SBU	477 66	146.40			
*Sbu		140.43	1		624 15
*s&n	19.11	60.62		1	70 72
*Sgn	123.63			3 3	19.13
*sgn	138.52			• 2	123.63
*SōU	758 02	77 100	1	•	138.52
*Sgn	76:00	11./02	1		966.03
*S0u					
		200000000000000000000000000000000000000			
	424.08	226.57		•	10000
	33.54	52.51			630.63
	91 63				86.05
	00:00	•	1	•	91.63
	38.38			,	000
Ĭ.	587.63	270.00			38.38

*Includes contractual interest payment based on interest rate prevailing at the end of the reporting period over the tenor of the borrowings.

Note 36: Capital management

For the purpose of the company's capital management, capital includes issued equity capital and all other equity reserves attributable to the equity holders of the company. The primary objective of the company's capital management is to ensure that it maintains an efficient capital structure and healthy capital ratios in order to support its business and maximise shareholder value.

The company manages its capital structure and makes adjustments to it in light of changes in economic conditions or its business requirements. To maintain or adjust the capital structure, the company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The company includes within net debt, interest bearing loans and borrowings less cash and short-term deposits (including other bank balances).

		Rs in Lakhs
Particulars	As at March 31, 2025	As at March 31, 2024
Interest-bearing loans and borrowings (Note 12) Less: Cash and Cash equivalent (including other bank balances) (Note 6(d) and 6(e))	601.94 (174.62)	117
Net debt	427.32	296.91
Equity share capital (Note 10)	889.46	889.46
Correl equity (NOTE II)	77.797.77	1,
Control and not dott	2,187.23	2,589.31
Caprical and net uebt	2,614.55	2,886.22
ספים וווק ופתוס	16.34%	10 200%

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements and other ratios. Breaches in meeting the financial covenants would permit the bank to charge penal interest or immediately call borrowings.

There have been no breaches in the financial covenants of borrowing as at March 31, 2025.

No changes were made in the objectives, policies or processes for managing capital during the years ended March 31, 2025 and March 31, 2024.

Note 37 : Ratio Analysis

Particulars	UOM Year Ended			100	Rs. in Lakhs
	ООМ	March 31,2025	March 31,2024	% Variance	exceeding 25% in absoult terms
i) Current Ratio :					Como
Current Assets (a)	Rs. in Lakhs	1,454,60	1,769.76		
Current Liabilities (b) Current Ratio (a/b)	Rs. in Lakhs Times	825.13	669.88		
Numerator - Total Current Assets Denominator - Total Current Liabilities	ilines	1.76	2.64	-33.27%	Decrease in current assets and increase in current liabilit
ii) Debt-Equity Ratio:					and increase in current liabilit
Debt (a)	0.20 10 1000				
Equity (b)	Rs. in Lakhs Rs. in Lakhs	601.94 2,187.23	609.08 2,589.31		
Debt - Equity Ratio (a/b)	%	27.52%	23.52%	17.00%	Not Applicable
Numerator - Total Debt Denominator - Total equity (Including perpetual Securities)					
ii) Debt Service coverage Ratio :					
Earnings available for Debt services (a)	Do in table				
nterest + Installments (b) Debt Service coverage Ratio (a/b)	Rs. in Lakhs Rs. in Lakhs	-207.38 532.49	144.78 467.21		
	%	-38.95%	30.99%	-225.68%	Due to increase in losses
lumerator - Profit after taxes and before Depreciation and Amortisation xpenses and Finance Costs (Int on Term Loan & Int on Lease) and othe					
dilistments like loss on sale of Fixed assets etc.	er				\$
enominator - Interest and Lease payments + Principal Repayment					
/) Return on Equity Ratio :					
rofit/(Loss) after Taxes quity (b)	Rs. in Lakhs Rs. in Lakhs	-402.54	-37.27		
eturn on Equity Ratio (a/b)	%	2,187.23 -18.40%	2,589.31 -1.44%	1178.61%	Due to increase in losses
umerator - Profit/(Loss) after Taxes - Distribution on Perpetual					Due to increase in losses
ecurities enominator - Average Shareholder's Equity					
Inventory Turnover Ratio :					
ost of Goods Sold/Sales (a)	De in Lakha	242.00			
verage Inventory (b) ventory Turnover Ratio (a/b)	Rs. in Lakhs Rs. in Lakhs	262.97 285.39	254.75 274.74		
	Times	0.92	0.93	-0.62%	Not applicable
umerator - Cost of Goods Sold/Sales enominator - (Openina Inventory+Closina Inventory)/2					
) Trade Receivables turnover Ratio :					
nual Net Credit Sales (a)	Rs. in Lakhs	1,491.96	1,420.42		
erade Accounts Receivable (b) ade Receivables turnover Ratio (a/b)	Rs. in Lakhs Times	472.13 3.16	512.51	0.51223	
merator - Net Credit Sales	Times	3.16	2.77	14.02%	Not applicable
nominator - (Opening trade receivable+Closing trade receivable)/2					
cluding unbilled revenue)					
) Trade Pavables turnover Ratio :					
sts (a) erage Accounts Pavable (b)	Rs. in Lakhs Rs. in Lakhs	298.62 107.63	146.40		8
de Pavables turnover Ratio (a/b)	Times	2.77	84.73 1.73	60.58%	Not Applicable
merator - Net Credit Purchase nominator - (Openina trade pavables+Closina trade pavables)/2					
i) Net Capital turnover Ratio :					
Sales (a)	Rs. in Lakhs	1,491.96	1 420 42		
rkino Capital (b) Capital turnover Ratio (a/b)	Rs. in Lakhs	629.47	1,420.42 1,099.88		
	%	237.02%	129.14%	83.53%	Decease in working capital
nerator - Net Sales nominator - Working Capital (Current Assets-Current Liabilities)					
oer i) Net Profit Ratio :					
fit/(Loss) after Tax (a)					
Sales (b)	Rs. in Lakhs Rs. in Lakhs	-402.54 1,491.96	-37.27 1,420.42		
Profit Ratio (a/b)	%	-26.98%	-2.62%	928.27%	Due to increase in losses
nerator - Profit/(Loss) after tax ominator - Net Sales					
Return on Capital Employed :					
ings before Interest and Taxes (a)	Rs. in Lakhs	-51.97	5.30		
tal Emploved (b) irn on Capital Emploved (a/b)	Rs. in Lakhs	2,941.21 -1.77%	3,318.88	1205 400	
erator - Earnings before Interest and Taxes	- (A)	-1.//70	0.16% -	1206.48%	Due to increase in losses
ominator - (Total Equity (Including Perpetual Securities) + Long term					



CIN: U24232GJ1960PLC000992 Notes to the Financial Statements

Note 38: Code on Social Security, 2020

The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Indian Parliament approval and Presidential assent in September 2020. The Code has been published in the Gazzete of India. However, the date on which the code will come into effect has not been notified. The Company will access the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.

Note 39: Recent Accounting Pronouncements to be adopted after March 31, 2025

There are no standards or interpretations which are notified but not yet effective and that would be expected to have a material impact on the Company in the current or future reporting periods.

Note 40: Other Notes

- a. During the year ended March 31, 2025 and March 31, 2024, the Company has not advanced or loaned or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:
- directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
- ii) provide any quarantee, security or the like to or on behalf of the ultimate beneficiaries.

Further, during the year ended March 31, 2025 and March 31, 2024, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- ii) provide any quarantee, security, or the like on behalf of the ultimate beneficiaries.
- b. The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.
- c. The Company has not invested or traded in Crypto Currency or Virtual Currency during the year ended March 31, 2025 (Previous year: Nil).
- d. No proceedings have been initiated on or are pending against the Company for holding benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) (formerly the Benami Transactions (Prohibition) Act, 1988 (45 of 1988)) and Rules made thereunder during the year ended March 31, 2025 (Previous year: Nil).
- e. The Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government authority during the year ended March 31, 2025 (Previous year: Nil).
- f. The Company has not surrendered or disclosed as income any transactions not recorded in the books of accounts in the course of tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961) during the year ended March 31, 2025 (Previous year: Nil).
- q. The Company does not have any transactions with the companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 during the year ended March 31, 2025 (Previous year: Nil).

Note 41: Events occurring after the reporting period

The Company evaluates events and transactions that occur subsequent to the balance sheet date but prior to the approval of financial statements to determine the necessity for recognition and/or reporting of subsequent events and transactions in the financial statements. As of May 17, 2025, there were no subsequent events and transactions to be recognized or reported that are not already disclosed.

Note 42: Regrouped, Recast, Reclassified

Material regroupings: Appropriate adjustments have been made in the statements of assets and liabilities, statement of profit and loss and cash flows, wherever required, by a reclassification of the corresponding items of income, expenses, assets, liabilities and cash flows in order to bring them in line with the groupings as per the audited financials of the Company as at March 31, 2025.

As per our report of even date For **Sorab S. Engineer & Co.** Chartered Accountants

Firm Registration No. 110417W

CA. Chokshi Shreyas B. Partner

Membership No. 100892

Ahmedabad Date: May 17, 2025 For and on behalf of Board of Directors of

Synbiotics Limited

Mohal K Sarabhai Managing Director DIN: 00334441

Salt Lake City, USA Date: May 17, 2025 Anurag Mehta Director DIN: 09756365

Vadodara

Date : May 17, 2025

SORAB S. ENGINEER & CO. (Regd.) CHARTERED ACCOUNTANTS

TELEPHONE: +91 79 48006782 :sbchokshi@sseco.in

sseahm@hotmail.com

WEB

: www.sseco.in



804-805, SAKAR-IX, BESIDE CITY GOLD. ASHRAM ROAD, AHMEDABAD-380 009

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF SYNBIOTICS LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Synbiotics Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, the loss and total comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report, but does not include the Ind AS financial statements and our auditor's report thereon.

Our opinion on the Ind AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to
 design audit procedures that are appropriate in the circumstances. Under section
 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether
 the Company has adequate internal financial controls system in place and the
 operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that individually or in aggregate, make it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

- 1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid financial statements comply with Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

olo

- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - The Company has disclosed the impact of pending litigations on its financial position in its financial statements;
- ii. The Company did not have any long-term contract including derivative contracts for which there were any material foreseeable losses
- There have been no amounts required to be transferred to the Investor Education and Protection Fund by the Company.

iv.

- 1. The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- 2. The management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- Based on the audit procedures conducted by us, nothing has come to our notice that has caused us to believe that the representations under subclause (i) and (ii) contain any material misstatements.
- v. According to the information and explanations provided to us, the Company has not declared any dividend during the year.
- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account which have a feature of recording audit trail facility and the audit trail feature has been operating throughout the year for all relevant transactions recorded in the software, except that audit trail was not enabled at the database level to log any direct data changes.

Additionally, the audit trail has been preserved by the company as per the statutory requirements for record retention. Our examination of the audit trail was in the context of an audit of financial statements carried out in accordance with the Standard of Auditing and only to the extent required by Rule 11(g) of



the Companies (Audit and Auditors) Rules,2014. We have not carried out any audit or examination of the audit trail beyond the matters required by the aforesaid Rule 11(g) nor have we carried out any standalone audit or examination of the audit trail.

2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

For Sorab S. Engineer & Co.

Chartered Accountants

Firm Registration No. 110417W

CA. Chokshi Shreyas B.

Partner

Membership No.100892

UDIN: 25100892BMIFHY8114

Ahmedabad May 17, 2025

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of Synbiotics Limited of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **SYNBIOTICS LIMITED** ("the Company") as of March 31, 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Me

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Sorab S. Engineer & Co.

Chartered Accountants

Firm's Registration No. 110417W

CA. Chokshi Shreyas B.

Partner

Membership No.100892

Ahmedabad May 17, 2025

ANNEXURE 'B' TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

- In respect of the Company's fixed assets:
 - a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
 - (B) The Company does not have intangible assets. Consequently, the requirements under sub-clause (b) to clause (i) of paragraph 3 of the order is not applicable.
 - b) The Company has a program of verification to cover all the items of Property, Plant and Equipment in a phased manner which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
 - c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favor of the lessee) disclosed in the financial statements are held in the name of the Company.
 - d) According to the information and explanations given to us, the Company has not revalued its Property, Plant and Equipment or intangible assets or both during the year.
 - e) According to the information and explanation given to us, the Company has no proceedings pending for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.
- ii. In respect of Company's Inventories:
 - a) As explained to us, physical verification of inventory has been conducted at reasonable intervals by the management and in our opinion the coverage and procedure of such verification is appropriate, and no material discrepancies were noticed on verification between the physical stocks and the book records which were 10% or more in the aggregate for each class of inventory, and the same have been properly dealt with in the books of account.
 - b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. Consequently, the requirements of clause (ii)(b) of paragraph 3 of the order are not applicable.
- iii. The Company has neither made any investments nor provided guarantee or granted secured / unsecured loans to companies, firms, Limited Liability Partnerships or other parties.



Consequently, reporting requirements under clause (iii) of paragraph 3 of the order are not applicable.

- iv. According to the information and explanations given to us and on the basis of our examination of the records, the Company has not advanced any loan or given any guarantee or provided any security or made any investment covered under section 185 and 186 of the Act.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of Sections 73 to 76 or any other relevant provisions of the Act and rules framed thereunder. No order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal.
- vi. According to the information and explanations given to us, the Central Government has not prescribed the maintenance of cost records under Section 148(1) of the Companies Act, 2013 for the products manufactured by it (and/ or services provided by it). Accordingly, clause 3(vi) of the Order is not applicable.
- vii. According to the information and explanations given to us, in respect of statutory dues:
 - a. The Company is generally regular in depositing with appropriate authorities undisputed statutory dues including Provident Fund, Employees' State Insurance, Income Tax, Wealth Tax, Custom Duty, Goods and Service Tax, Cess and other material statutory dues applicable to it. According to the information and explanations given to us, no undisputed amounts payable in respect of outstanding statutory dues were in arrears as at March 31, 2025 for a period of more than six months from the date they became payable.
 - b. Following amounts have not been deposited as on March 31, 2025 on account of dispute:

Nature of Statute	Nature of dues	Rs. in Lakhs	Period to which the amount relates	Forum where matter is pending
Income tax Act, 1961	Income tax	120.16	2008-2009, 2012-2013	High Court
Employee State Insurance Act	Employee State Insurance	81.35	2010-2011	High Court
Central Goods and Service Tax Act, 2017	Goods and Service Tax	14.45	2017-18	GST Commissioner, Vadodara
Provident Fund Act	Provident Fund Damages	20.95	2012-2013	CGIT(A)

- viii. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.
- ix. In our opinion and according to the information and explanations givens to us, in respect of Company's Borrowings:
 - a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
 - b) The Company is not a declared willful defaulter by any bank or financial institution or other lender.
 - c) The Company has applied the term loans for the purpose for which the loans were obtained.



- d) The funds raised on short term basis have not been utilized for long term purposes.
- e) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiary.
- f) The Company has not raised loans during the year on the pledge of securities held in its subsidiary.
- x. In our opinion and according to the information and explanations given to us, the Company has not raised funds by way of initial public offer or further public offer (including debt instruments) or preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year. Consequently, the requirements of clause (x) of paragraph 3 of the order are not applicable.
- xi. In respect of fraud by the Company or on the Company:
 - a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
 - b) According to the information and explanations given to us, no report under subsection (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - c) There have been no whistle-blower complaints received during the year by the Company.
- xii. According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- xiii. In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of the Act, where applicable, and the details have been disclosed as required by the applicable Indian Accounting Standard (Ind AS)-24 Related Party Disclosures.
- xiv. To the best of our knowledge and belief and according to the information and explanations given to us, the Company is not required to have internal audit. Consequently, reporting requirements under Clause (xiv) of the paragraph of the order are not applicable.
- xv. In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi. a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) and (b) of the Order are not applicable.
 - b) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) and (d) of the Order are not applicable.

who

- xvii. According to the information and explanations given to us, The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- xviii. According to the information and explanations given to us, there has been no resignation of the statutory auditors during the year.
- xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx. (a) In respect of other than ongoing projects, the Company has yet not transferred unspent amount to a Fund specified in Schedule VII to the Companies Act, 2013 within a period of six months of the expiry of the financial year in compliance with second proviso to sub-section (5) of section 135 of the said Act, details of which are as follows:

Financial year	Responsibility activities "other	Amount Transferred to Fund specified in Schedule VII within 6 months from the end of the Financial Year	Transferred
2022-23	0.24 Rs. in Lacs	Nil	Nil

- (b) There is no amount remaining unspent under section (5) of section 135 of Companies Act, pursuant to any ongoing project, thus requirement of clause (xx)(b) is not applicable;
- xxi. The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of Financial Statements. Accordingly, no comment in respect of the said clause has been included in this report.

For Sorab S. Engineer & Co.

Chartered Accountants

Firm's Registration No. 110417V

CA. Chokshi Shreyas B.

Partner

Membership No.100892

Ahmedabad May 17, 2025